Stock KYTX KYVERNA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Kyverna Therapeutics, Inc.

Equities

KYTX

US5019761049

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-28 pm EDT 		5-day change 1st Jan Change
13.23 USD +1.77% Intraday chart for Kyverna Therapeutics, Inc. -3.43% 0.00%
May. 14 Kyverna Therapeutics Q1 Loss Narrows MT
Apr. 25 Nasdaq's revenue beats on strong demand for fintech products RE

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Kyverna Therapeutics Q1 Loss Narrows
MT
Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
PR
Nasdaq's revenue beats on strong demand for fintech products
RE
First-in-Disease Use of Kyverna Therapeutics KYV-101 in Patients with Progressive Multiple sclerosis Published in Med1
AQ
First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in Med
PR
Kyverna Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results
PR
Kyverna Therapeutics, Inc.(NasdaqGS:KYTX) added to S&P TMI Index
CI
Sector Update: Health Care Stocks Steady Pre-Bell Friday
MT
Kyverna Therapeutics Teams Up With Stanford University to Evaluate Investigational Multiple Sclerosis Drug
MT
Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis
PR
Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis
CI
JPMorgan Initiates Kyverna Therapeutics With Overweight Rating
MT
Morgan Stanley Starts Kyverna Therapeutics With Overweight Rating
MT
Kyverna Therapeutics Closes $366.9 Million Initial Public Offering
MT
Kyverna Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
PR
Moderna, Bayer-backed Metagenomi stock drops 32% on Nasdaq debut
RE
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. KYTX Stock
  4. News Kyverna Therapeutics, Inc.